Background: Memantine is an -methyl--aspartate (NMDA) receptor antagonist that is used to treat moderate to severe Alzheimer's Dementia (AD) and has been speculated to provide clinical benefits in Huntington's disease (HD).
Objective: To assess the effectiveness of memantine on the trajectory of cognitive decline in individuals with manifest HD.
Methods: Using participants from the Enroll-HD study, the primary analysis compared trajectories in cognition over a 5-year period using linear mixed effect models of prevalent and incident memantine users who were propensity-score-matched with non-users on measures of disease progression and demographics.
Results: In the primary analysis there were no significant differences in the trajectories between memantine users and non-users on any primary outcomes of interest.
Conclusions: Memantine use was not associated with any clinical benefit for individuals with manifest HD. Further studies are warranted to assess the impact of memantine on clinical outcomes in HD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354618 | PMC |
| http://dx.doi.org/10.1002/mdc3.13763 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Computerized cognitive testing to capture cognitive decline in Alzheimer's disease: Longitudinal findings from the ARMADA study.
Alzheimers Dement (Amst)
January 2025
Department of Neurology Massachusetts General Hospital, Harvard Medical School Boston Massachusetts USA.
Introduction: Timely detection and tracking of Alzheimer's disease (AD) -related cognitive decline has become a public health priority. We investigated whether the NIH Toolbox for Assessment of Neurological and Behavioral Function-Cognition Battery (NIHTB-CB) detects AD-related cognitive decline.
Methods: = 171 participants (age 76.
Modifiable risk factors and symptom progression in dementia over up to 8 years-Results of the DelpHi-MV trial.
Alzheimers Dement (Amst)
January 2025
Health Care Research Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Greifswald Mecklenburg-Vorpommern Germany.
Introduction: This study investigated the association between modifiable factors and symptom progression in dementia over up to 8 years.
Methods: Multilevel growth curve models assessed the role of modifiable risk factors (low education, hearing impairment and its treatment, depression, physical inactivity, diabetes and its treatment, smoking, hypertension and its treatment, obesity, alcohol consumption, social isolation, and visual impairment) on cognitive and functional trajectories in 353 people with dementia.
Results: Higher education was associated with higher initial cognitive status but faster decline.
Cumulative blood pressure load and cognitive decline in older adults: An observational analysis of two large cohorts.
Cereb Circ Cogn Behav
December 2024
The George Institute for Global Health, Sydney, Australia.
Introduction: Cumulative blood pressure metrics may provide greater precision for measuring temporal risk exposure, especially in later life where data are mixed regarding associations of high blood pressure (BP) on cognitive function. We examined the relationship between greater cumulative exposure to high BP in later life and several domains of cognitive function.
Methods: Individual cognitive assessment scores and BP measurements in older adults (age ≥70 years) at baseline and over approximately 8 years of follow-up were available in the population-based Canadian Victoria Longitudinal Study (VLS) and Swedish Gothenburg H70 Birth Cohort Studies (H70).
A measure of modifiable lifestyle factors shaping subjective cognitive reserve in the general population.
Front Psychol
December 2024
Department of Neurology, Harvard Medical School, Boston, MA, United States.
Objective: This study examined the psychometric properties of a newly developed scale for measuring subjective cognitive reserve (SCR) across multiple domains, including nutrition, physical condition, sleep, cognition, willingness to learn, socialization, general health, and life plan.
Method: The relationship between SCR scores and other established measures of cognitive reserve and subjective cognitive decline was also explored. A sample of 402 healthy participants aged 18 to 79 years took part in the study.
Alzheimer's disease (AD) is the most prevalent neurodegenerative dementia, marked by progressive cognitive decline and memory impairment. Despite advances in therapeutic research, single-target-directed treatments often fall short in addressing the complex, multifactorial nature of AD. This arises from various pathological features, including amyloid-β (Aβ) aggregate deposition, metal ion dysregulation, oxidative stress, impaired neurotransmission, neuroinflammation, mitochondrial dysfunction, and neuronal cell death.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!